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E-mail address: ryu@mcg.edu (R.K. Yu).Stem cells, such as embryonic stem cells, hematopoietic stem cells, neural stem cells, mesenchymal
stem cells, and very small embryonic-like stem cells, are undifferentiated cells that are endowed
with a high potential for proliferation and the capacity for self-renewal with retention of pluri/mul-
tipotency to differentiate into their progenies. Recently, studies regarding the biological functions of
glycolipids and cell surface microdomains (caveolae, lipid rafts, or glycolipid-enriched microdo-
mains) in stem cells are emerging. In this review, we introduce the expression patterns of glycolipids
and the functional roles of cell surface microdomains in stem cells.
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Glycolipids are lipid molecules linked with one or more carbo-
hydrate units. Based on their core lipid moiety, glycolipids are clas-
siﬁed into glycosphingolipids (containing ceramide) and
glycoglycerolipids (containing glycerol). Glycosphingolipids (GSLs)
containing sialic acid residue(s) are referred to as gangliosides. Gly-
colipids are found in virtually all vertebrate cells and body ﬂuids
and are localized primarily, but not exclusively, on the plasma
membrane. One of notable characteristics of glycolipids is the
structural diversity; so far, 172 neutral GSLs, 24 sulfated GSLs,
and 188 gangliosides with variations in the carbohydrate chain
have been reported in vertebrate tissues and organs [1]. Their com-
plexity may increase manifold when variations in their lipophilic
components are taken into consideration. The expression patterns
of glycolipids are known to change drastically during development
or cellular differentiation. Therefore, glycolipids have been fre-
quently used as important developmental marker molecules.
Glycolipids have also been suggested to play important biolog-
ical functions. Mouse embryos deﬁcient in glucosylceramide syn-
thase, which catalyzes the initial step of GSL biosynthesis, are
able to differentiate into endoderm, mesoderm, and ectoderm
but are unable to form more differentiated tissues and die during
midgastrulation by apoptosis in the ectoderm [2]. Although neuralchemical Societies. Published by Ecell-speciﬁc disruption of glucosylceramide synthase does not im-
pair late embryonic development, all glucosylceramide synthase-
deﬁcient mice die within 24 days after birth by dysfunction of
cerebellum and peripheral nerves, associated with structural de-
fects. This strongly indicates that GSLs are required for brain mat-
uration after birth [3]. Mice deﬁcient in ganglioside synthases are
basically viable but exhibit multiple defects such as a lethal
sound-induced seizure in GD3 synthase-/GM2 synthase-double
knockout mice and a hearing loss in GM3 synthase-knockout mice
[4,5] (for further details and discussions of the mice deﬁcient in
ganglioside synthases, see [6]). Also in humans, a nonsense muta-
tion of GM3 synthase causes autosomal recessive infantile-onset
symptomatic epilepsy syndrome [7]. These studies revealed that
mutation of GSL-synthesis enzymes leading to the absence of spe-
ciﬁc GSL structures and accumulation of certain precursor GSLs.
The consequences are manifested with developmental abnormali-
ties, leading to certain clinical consequences and death. They fur-
ther reinforce the concept that plasma membrane glycolipids are
crucial in developmental events by playing important biological
functions, such as modulation of cell signaling and cell–cell inter-
action. On the plasma membrane, glycolipids are believed to clus-
ter with other membrane lipids, such as cholesterol and
sphingomyelin, to form specialized microdomains termed caveo-
lae, lipid rafts, or glycolipid-enriched microdomains [8–11]. In
these microdomains, signaling and cell-adhesion molecules are
localized, implicating that these domains may form platforms for
signal transduction and cell adhesion.lsevier B.V. All rights reserved.
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functions of glycolipids and cell surface microdomains in
stem cells are emerging. A stem cell is deﬁned as an undifferen-
tiated cell endowed with a high potential for proliferation and
the capacity for self-renewal with retention of pluripotency or
multipotency to differentiate into their progenies. Stem cells
represent cellular reservoirs for formation of tissues and organs
during development and for replacement of cells lost during
normal cellular turnover in adulthood. Stem cells are roughly
classiﬁed into two types: embryonic stem cells and somatic stem
cells. An embryonic stem cell is derived from epiblasts in the
inner cell mass of blastocysts and has a pluripotency to generate
all cells in three germ layers, endoderm, mesoderm, and
ectoderm. Somatic stem cells are multipotent cells which can
restrictively differentiate into a related group of cells. As the
representative somatic stem cells, hematopoietic stem cells, neu-
ral stem cells, and mesenchymal stem cells are well known. In
addition to these stem cells, induced pluripotent stem cells (iPS
cells), pluripotent stem cells artiﬁcially generated from mouse so-
matic cells such as ﬁbroblasts by introducing Oct3/4, Sox2, c-Myc,
and Klf4 have recently been established [12]. These stem cells
have attracted a great interest lately, owing to their potential in
unlocking speciﬁc cellular events leading to differentiation, prolif-
eration, and fate determination. Furthermore, it has been hypoth-
esized that there is a sub-population of particular cancer cells
having stem cell-like characteristics such as self-renewal and
differentiation capacity and continually sustaining tumorigenesis
in primary tumors. These stem cell-like cancer cells are referred
to as cancer stem cells. Recently, cancer stem cells have been iso-
lated from tumors. Cancer stem cells, namely tumor-initiating
cells or tumor-propagating cells, can be important targets for
cancer treatment.
In the stem cells, it has been expected that glycolipids and cell
surface microdomains play important roles as markers and func-
tional molecules. In this review, we will introduce the expression
patterns of glycolipids and the functional roles of the cell surface
microdomains in stem cells. The structures of the glycolipids and
the glycolipid expressions in stem cells referred to in this paper
are presented in Tables 1 and 2.Table 1
Structures and nomenclature of glycosphingolipids referred to in this paper. The nomencl
Abbreviation Series Structure
Asialo-GM1 asialo-series
Fucosyl-GM1
GM3 a-series
GM2 a-series
GM1 a-series
GD1a a-series
GalNAc-GD1a a-series
GT1a a-series
GT1aa a-series
GD3 b-series
9-O-acetyl-GD3 b-series
GD2 b-series
GD1b b-series
GT1b b-series
GQ1b b-series Neu5Ac
GQ1ba b-series Neu5Ac
GT3 c-series
GT2 c-series
GT1c c-series
GQ1c c-series Neu5Ac
GP1c c-series Neu5Aca2,8Neu5Ac
SSEA-1
SSEA-3
SSEA-42. Glycolipids expressed in stem cells
2.1. Glycolipids expressed in embryonic stem cells
In undifferentiated E14 mouse embryonic stem cells, it has been
biochemically elucidated that a-series gangliosides, GM3, GM1,
and GD1a, are expressed [13]. On the other hand, it has also been
reported that GM1 is exclusively expressed in J1 mouse embryonic
stem cells [14]. During differentiation, the concentration of gan-
gliosides is increased and the expression pattern of gangliosides
becomes more complex, with GD3 predominating initially and a-
and b-series emerging at the expense of GD3 [13]. One of the unu-
sual differentiation-related gangliosides in E14 ES cells is GalNAc-
GD1a, which was identiﬁed by fast-atom bombardment mass spec-
trometry [13]. With respect to neutral GSLs expressed in undiffer-
entiated mouse embryonic stem cells, lactosylceramide, ceramide
trihexoside, globoside, and forssman antigen have been identiﬁed
[13]. In H7 human embryonic stem cells, a ﬂow cytometric study
revealed that globo-series GSLs, stage speciﬁc embryonic anti-
gen-3 (SSEA-3) and SSEA-4, are also expressed [15]. These antigens
are down-regulated following induction of differentiation with
concomitant increase in expression of the b-series gangliosides,
GD3, 9-O-acetyl-GD3 and GD2, and c-series gangliosides.
SSEA-1 is a trisaccharide antigen recognized by a monoclonal
antibody against embryonal carcinoma cells [16]. It is well recog-
nized that mouse embryonic stem cells express the SSEA-1 antigen
[17,18]. It has also been reported that iPS cells are positive for
SSEA-1 [12]. The SSEA-1 carbohydrate epitope is carried by glyco-
proteins, proteoglycans and glycolipids [19]. However, in the
teratocarcinoma cell lines, glycoproteins rather than glycolipids
are the major carrier molecules of SSEA-1 [20]. Interestingly,
SSEA-1 is not expressed in human embryonic stem cells; SSEA-3
and SSEA-4 are expressed in these cells [21]. In contrast, SSEA-3
and SSEA-4 are not expressed in mouse embryonic stem cells.
Glycolipids expressed in embryonal carcinoma cells, stem cells
in teratocarcinoma, have also been reported. In mouse P19 embry-
onal carcinoma cells, trace amounts of GM3 and GD3 are expressed
[22,23]. However, after neuronal differentiation induced by
retinoic acid, the total ganglioside amount was elevated, andature for gangliosides is based on that of Svennerholm [58].
Galb1,3GalNAcb1,4Galb1,4Glcb1,1Cer
Fuca1,2Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4Glcb1,1Cer
Neu5Aca2,3Galb1,4Glcb1,1Cer
GalNAcb1,4(Neu5Aca2,3)Galb1,4Glcb1,1Cer
Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4Glcb1,1Cer
Neu5Aca2,3Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4Glcb1,1Cer
GalNAcb1,4(Neu5Aca2,3)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4Glcb1,1Cer
Neu5Aca2,8Neu5Aca2,3Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4Glcb1,1Cer
Neu5Aca2,3Galb1,3(Neu5Aca2,6)GalNAcb1,4(Neu5Aca2,3)Galb1,4Glcb1,1Cer
Neu5Aca2,8Neu5Aca2,3Galb1,4Glcb1,1Cer
Neu5,9Ac2a2,8Neu5Aca2,3Galb1,4Glcb1,1Cer
GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4Glcb1,1Cer
Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4Glcb1,1Cer
Neu5Aca2,3Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4Glcb1,1Cer
a2,8Neu5Aca2,3Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4Glcb1,1Cer
a2,3Galb1,3(NeuAca2,6)GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4Glcb1,1Cer
Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4Glcb1,1Cer
GalNAcb1,4(Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3)Galb1,4Glcb1,1Cer
Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3)Galb1,4Glcb1,1Cer
a2,3Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3)Galb1,4Glcb1,1Cer
a2,3Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3)Galb1,4Glcb1,1Cer
Galb1,4(Fuca1,3)GlcNAcb1,3Galb1,4Glcb1,1Cer
Galb1,3GalNAcb1,3Gala1,4Galb1,4Glcb1,1Cer
Neu5Aca2,3Galb1,3GalNAcb1,3Gala1,4Galb1,4Glcb1,1Cer
Table 2
Glycolipids expressed in stem cells.
Stem cells Species Glycolipid Reference
Embryonic stem cell Mouse GM3 [13]
GM1 [13,14]
GD1a [13]
Lactosylceramide [13]
Ceramide trihexoside [13]
Globoside [13]
Forssman antigen [13]
SSEA-1 [17,18]
Human SSEA-3 [15,21]
SSEA-4 [15,21]
Induced pluripotent stem cell Mouse SSEA-1 (glycoprotein/proteoglycan?) [12]
Neural stem cell Mouse, human GD2 [30]
Mouse GD3 [31]
GQ1b [31]
GT1b [31]
Chol-1a (GT1aa and GQ1ba) [32]
Mouse SSEA-1 (glycoprotein/proteoglycan?) [30,34]
Human SSEA-1 (glycoprotein/proteoglycan?) [30]
Brain cancer stem cell Human A2B5 antigens (c-series gangliosides) [35,36]
Mouse SSEA-1 (glycoprotein/proteoglycan?) [37,38]
Human SSEA-1 (glycoprotein/proteoglycan?) [39]
Hematopoietic stem cell Mouse GM1? [42–44]
Mesenchymal stem cell Human GD2 [46]
GM1 [14]
GM3 [48]
GM2 [48]
GD1a [48]
Mouse, human SSEA-4 [45]
Very small embryonic-like stem cell Mouse SSEA-1 (glycoprotein/proteoglycan?) [49]
Human SSEA-4 [50]
1696 R.K. Yu et al. / FEBS Letters 584 (2010) 1694–1699expression of GM2, GM1, GD1a, GD1b, GT1b, and GQ1b was
up-regulated in these cells. In 2102Ep human teratocarcinoma
cells, globo-series GSLs such as globotriaosylceramide, globotet-
raosylceramide (globoside), globopentaosylceramide (SSEA-3),
fucosyl-globopentaosylceramide (SSEA-3), and sialyl-globopentao-
sylceramide (SSEA-3 and SSEA-4) have been characterized [24]. In
addition, fucosyl-globoside and sialyl-globoside have been found
in HT-E (833 K) human teratocarcinoma cells [25]. It is interesting
to note that globo-series GSLs are related to cellular differentiation
[26].
2.2. Glycolipids expressed in neural stem cells
Neural stem cells aremultipotent cells generating brain-forming
cells such as neurons and glial cells; the latter include astrocytes
and oligodendrocytes [27]. Neural stem cells appear in the neuroep-
ithelium during development and are located in the subventricular
zone of the lateral ventricles and the subgranular layer of the den-
tate gyrus in the hippocampus in adulthood [28,29]. There are stud-
ies reporting the expression of glycolipids in these cells [27].
In mouse and human neural stem cells, the expression of a b-
series ganglioside, GD2, was detected by ﬂow cytometric analysis
[30]. By a biochemical study of the mouse neuroepithelial cells that
are known to be rich in neural stem cells, it was determined that
another b-series ganglioside, GD3, is the predominant gangliosides
[31]. In addition, GQ1b, GT1b, and Chol-1a gangliosides (GT1aa
and GQ1ba) are also expressed in the neuroepithelial cells in much
lesser amount [31–33]. Interestingly, a-series gangliosides such as
GM1 and GD1a are not detectable in the neuroepithelial cells, but
are up-regulated after neuronal differentiation [32]. In mouse and
human neural stem cells, a fucosylated carbohydrate antigen,
SSEA-1 is also expressed [30,34]. It has been found that the
SSEA-1 antigen in neuroepithelial cells is carried not only by glyco-
proteins, but also by glycolipids [33].2.3. Glycolipids expressed in cancer stem cells
Recently, glycolipids characterizing cancer stem cells in brain tu-
mors have been reported. In human glioma such as glioblastoma,
astrocytoma, oligodendroglioma, and ependymoma, the cancer
stem cells are positive for A2B5 antigens, c-series gangliosides such
as GT3, GT2, GQ1c, and GP1c [35,36]. It has been conﬁrmed by xeno-
graft experiments that A2B5+ cells isolated from human glioblas-
toma by ﬂuorescence-activated cell sorting (FACS) or magnetic cell
sorting can form tumors in brains of nude rats ormice. These studies
clearly indicate the usefulness of c-series gangliosides as marker
molecules to identify brain cancer stem cells. In addition to c-series
gangliosides, SSEA-1 has also been found in cancer stem cells. Tu-
mors from Patched mutant mice, a mouse model of medulloblas-
toma, has been reported to highly express SSEA-1 [37,38]. SSEA-1+
cells collected from the tumors by FACS gave rise to tumors in the
brains of all SCID/beige mice after implantation. A subset of human
medulloblastoma was conﬁrmed to be positive for SSEA-1. Also, in
human glioblastoma multiforme cells, SSEA-1-positive populations
have been reported to be the cancer stem cells [39]. In this study, it
was found that SSEA-1+ cells sorted from human glioblastoma
multiforme by magnetic cell sorting and injected into the brains of
NOD-SCID mice generated tumors more efﬁciently than SSEA-1
cells. These ﬁndings suggest that SSEA-1 is a generalmarker antigen
of cancer stem cells in brain tumors. The carriermolecules of SSEA-1
in these tumor stem cells have not yet been characterized, but there
might be a possibility that they are glycolipids.
2.4. Glycolipids expressed in hematopoietic stem cells
Hematopoietic stem cells are multipotent cells which can give
rise to cells forming blood and immune systems, such as myeloids
(erythrocytes, basophils, eosinophils, neutrophils, monocytes,
macrophages, megakaryocytes, and platelets), and lymphoids
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originally appear in the aorta-gonad-mesonephros in embryos
and then are located in the bone marrow in adults.
So far there has not been biochemical analysis of glycolipids ex-
pressed in hematopoietic stem cells, probably because they are in
very low abundance in bone marrow (mouse bone marrow hema-
topoietic stem cells account for 0.004% of bone marrow mononu-
clear cells) [40]. However, in rat lymphocyte progenitor cells
prepared from bone marrow by Ficoll–Paque density centrifuga-
tion, the expression of gangliosides has been quantiﬁed by bio-
chemical analysis [41]. The contents of each ganglioside fraction
are as follows: monosialogangliosides, 22.8 ± 1.8%; disialoganglio-
sides-1, 17.7 ± 1.6%; disialogangliosides-2, 15.8 ± 1.3%; trisialogan-
gliosides, 19.3 ± 2.0%; and tetrasialogangliosides, 24.4 ± 1.9%. The
molecular species of these gangliosides have not yet been identi-
ﬁed. Furthermore, it has been found that cholera toxin B subunit,
a molecular probe recognizing GM1, are reactive with mouse
hematopoietic stem cells [42–44], which suggests the presence of
GM1 in these cells. However, it is known that the cholera toxin
B-subunit is reactive with not only GM1, but also to a much lesser
extent with other glycolipids, such as GD1a, asialo-GM1, fucosyl-
GM1, GM2, GD1b, GT1b, and GM3. The possibility that hematopoi-
etic stem cells express these gangliosides cannot be ruled out. To
identify bona ﬁde gangliosides expressed in hematopoietic stem
cells, systematic biochemical studies are required.
2.5. Glycolipids expressed in mesenchymal stem cells
Mesenchymal stem cells are multipotent stromal cells which
can differentiate into cells of the mesodermal lineage such as myo-
cytes, osteocytes, adipocytes, and chondrocytes. These cells can be
isolated from all mesenchymal tissues, especially bone marrow. It
has been reported that the SSEA-4 carbohydrate epitope is ex-
pressed in adult mouse and human mesenchymal stem cells and
is useful for isolating these cells from bone marrow [45]. It was
found in this study that SSEA-4+ cells isolated from mouse and hu-
man bone marrow cells by FACS have a high proliferative ability
and a multipotency to differentiate into adipocytes and osteo-
blasts. Furthermore, an immunocytochemical and ﬂow cytometric
analysis revealed that GD2 is speciﬁcally expressed in human mes-
enchymal stem cells isolated from bone marrow and adipose tis-
sue, but not in unfractionated bone marrow cells, CD45+
leukocytes, CD34+ hematopoietic progenitor cells, CD33+ myeloid
cells, CD3+ T-lymphocytes, and CD19+ B-lymphocytes [46]. It has
been conﬁrmed that GD2+ cells isolated from bone marrow using
immunomagnetic beads have the characteristics of mesenchymal
stem cells such as the morphology, plastic adherence ability, and
multipotency to differentiate into osteoblasts, adipocytes, and
chondroblasts. In addition, mesenchymal stem cells isolated from
human umbilical cord blood have been reported to be positive
for GD2 [47]. These ﬁndings clearly indicate the expression of
GD2 in human mesenchymal stem cells and its usefulness as a
marker molecule. However, it has also been reported that GM1 is
expressed in human mesenchymal stem cells prepared from peri-
odontal bone marrow [14]. Recently, it also has been reported that
GM3, GM2, and GD1a are expressed in human dental pulp-derived
stem cells which share molecular and cellular characteristics with
bone marrow-derived mesenchymal stem cells; during neuronal
differentiation, GD3 is up-regulated [48]. It still remains to be
undetermined whether the predominant ganglioside expressed in
human mesenchymal stem cells is GD2 or other gangliosides.
2.6. Glycolipids expressed in very small embryonic-like stem cells
Very small embryonic-like stem cells (VSELs) are adult versatile
cells, which were originally found in mouse bone marrow andhuman umbilical cord blood [49–51]. VSELs express embryonic
stem cell markers such as Oct3/4 and Nanog and have pluripotency
to differentiate into cells of all three germ layers (i.e., cardiomyo-
cytes, neurons, astrocytes, oligodendrocytes, and pancreatic cells)
in vitro like embryonic stem cells [49]. The most interesting char-
acteristic of these cells is the size; the diameter of the cell body is
just 2–4 lm in mice and 3–5 lm in human. VSELs were identiﬁed
not only in bone marrow, but also in organs such as brains, kid-
neys, pancreas, and skeletal muscles in mice [51].
VSELs are found in a population of CXCR4+ Sca-1+ lineage
marker CD45 cells in adult mouse bone marrow, and a popula-
tion of CXCR4+ CD133+ CD34+ lineage marker CD45 cells in hu-
man umbilical cord blood [49,50]. In addition to these markers,
SSEA-1 and SSEA-4 are expressed in mouse and human VSELs,
respectively. It is interesting that the expression patterns of these
antigens are similar to those in mouse and human embryonic stem
cells. It is not yet clear whether the carrier molecule of SSEA-1 in
the mouse VSELs is a glycolipid, but the molecular characteristics
are expected to be similar with those in mouse embryonic stem
cells. The immunoreactivity of SSEA-1 in mouse VSELs after perme-
abilization with Triton X-100 which can easily wash out glycolipid
antigens on the cell surface [49] suggests that the SSEA-1 carrier
molecules in these cells are mainly glycoproteins.3. Cell surface microdomains in stem cells
3.1. Cell surface microdomains in hematopoietic stem cells
Long-term hematopoietic stem cells in the bone marrow niche
are in a non-cycling state. In this hibernation or dormancy state of
hematopoietic stem cells, cell surfacemicrodomains play an impor-
tant role [42]. In CD34 c-Kit+ Sca-1+ lineagemarkerhematopoietic
stem cells freshly isolated from the bone marrow niche, cell surface
microdomains positive for GM1 are diffusely distributed [44]. Stim-
ulation by cytokines, stem cell factor and thrombopoietin, induces
clustering of cell surface microdomains and re-entry into the cell
cycle, probably via segregation and concentration of the activated
cytokine receptors. The factor from the nichewhich inhibits cell sur-
face microdomain clustering and induces the hibernation of hema-
topoietic stem cells has been identiﬁed as transforming growth
factor-b [52]. These studies clearly indicate the importance of cell
surface microdomain as platforms to integrate the signals for the
cells to maintain in a hibernation state.
Rac GTPases are known to be essential for ﬁlamentous-actin
assembly and chemotaxis of hematopoietic stem/progenitor cells.
It has been reported that disruption of cell surface microdomains
with methyl-b-cyclodextrin suppresses the translocation of Rac1
to cell surface microdomains and the assembly of ﬁlamentous-ac-
tin in c-Kit+ hematopoietic progenitor cells derived from mouse
low-density bone marrow [43]. This study suggests that cell sur-
face microdomains are also involved in chemotaxis of hematopoi-
etic stem/progenitor cells.
It has been suggested that the number of stem cells in physio-
logical condition is regulated by a balance between symmetric
and asymmetric cell division. Cell surface microdomains have been
implicated also in polarization of human CD34+ hematopoietic
stem/progenitor cells [53].
3.2. Cell surface microdomains in neural stem cells
In mouse neuroepithelial cells, cell surface microdomains have
been reported to be involved in signal transduction and cell adhe-
sion [31]. In these cells, disruption of cell surface microdomains
with methyl-b-cyclodextrin suppressed basic ﬁbroblast growth
factor-induced activation of the Ras-mitogen-activated protein
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tion, disruption of cell surface microdomains inhibited the cell
adhesion via b1 integrin which is localized in these microdomains.
It has also been suggested that cell surface microdomains in mouse
neurospheres act as integrators of the signal crosstalk by integrin,
growth factors, and Notch, which are important for the cell fate
regulation [54].
In mid-embryonic to early-postnatal stages of developing
mouse cortex, astroglial lineage cell surface microdomains are
characterized by enrichment of phosphatidylglucoside (PtdGlc), a
phosphoglycerolipid containing glucose linked to phosphatidic
acid [55,56]. It has been recently suggested that the PtdGlc-rich
cell surface microdomains are involved in astrocytogenesis during
development [57]. Treatment of mouse neural stem cells with anti-
PtdGlc antibody causes recruitment of epidermal growth factor
receptor into cell surface microdomain compartments with subse-
quent activation of the downstream signaling pathway. Therefore,
PtdGlc-rich cell surface microdomains are physiologically coupled
and regulate the activation of epidermal growth factor receptor on
neural stem cell during development.
4. Closing remark
In recent years, major progresses have been made in stem cell
biology, including generation of iPS cells from somatic cells.
Although many unresolved issues remain, such as low success rate
and safety concerns, application of cell-based transplantation using
stem cells is a very attractive and promising strategy for regenera-
tive and restorative medicine. The identiﬁcation of stem cell mar-
ker, especially those located on the plasma membrane, is becoming
increasingly important for the isolation and classiﬁcation of spe-
ciﬁc populations of stem cells. As we described above, speciﬁc gly-
colipids detected on each stem cell type are used for this purpose.
Additionally, understanding the functional role of glycolipids dur-
ing cellular differentiation and proliferation remains to be an
important area of research. Such information will undoubtedly
stimulate the progresses in developing stem cell-based therapeutic
strategies for a variety of degenerative diseases or tissue damage.
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